0000899243-20-029694.txt : 20201029 0000899243-20-029694.hdr.sgml : 20201029 20201029165901 ACCESSION NUMBER: 0000899243-20-029694 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201027 FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOTTSCHALK ADRIAN CENTRAL INDEX KEY: 0001828724 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 201273422 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: SUITE 610 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-27 0 0001822462 Foghorn Therapeutics Inc. FHTX 0001828724 GOTTSCHALK ADRIAN 500 TECHNOLOGY SQUARE, STE 700 CAMBRIDGE MA 02139 1 1 0 0 See Remarks Common Stock 2020-10-27 4 C 0 25225 A 25225 I See Footnote Series A-2 Convertible Preferred Stock 2020-10-27 4 C 0 18018 D Common Stock 18018 0 I See Footnote Series B Convertible Preferred Stock 2020-10-27 4 C 0 7207 D Common Stock 7207 0 I See Footnote The Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. Shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee. President & Chief Executive Officer By: /s/ Allan Reine, M.D., Attorney-in-Fact 2020-10-29